Pulmonx (NASDAQ:LUNG) Posts Quarterly Earnings Results, Beats Expectations By $0.12 EPS

Pulmonx (NASDAQ:LUNG) released its quarterly earnings data on Wednesday. The company reported ($0.33) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.12, Zacks reports. Pulmonx had a negative net margin of 72.01% and a negative return on equity of 53.88%. Pulmonx updated its FY 2025 guidance to EPS.

Pulmonx Price Performance

Shares of LUNG traded down $0.35 during mid-day trading on Wednesday, hitting $6.64. 565,488 shares of the company were exchanged, compared to its average volume of 230,734. The stock has a market cap of $262.21 million, a price-to-earnings ratio of -4.52 and a beta of 0.64. Pulmonx has a 1-year low of $5.46 and a 1-year high of $14.60. The company has a 50 day moving average of $6.42 and a 200-day moving average of $6.74. The company has a debt-to-equity ratio of 0.40, a quick ratio of 6.77 and a current ratio of 7.70.

Insider Buying and Selling

In other Pulmonx news, Director Glendon E. French III sold 20,000 shares of the firm’s stock in a transaction on Friday, November 22nd. The stock was sold at an average price of $6.63, for a total value of $132,600.00. Following the transaction, the director now owns 1,071,974 shares in the company, valued at approximately $7,107,187.62. This trade represents a 1.83 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, General Counsel David Aaron Lehman sold 5,497 shares of the company’s stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $6.19, for a total transaction of $34,026.43. Following the sale, the general counsel now directly owns 197,851 shares of the company’s stock, valued at $1,224,697.69. The trade was a 2.70 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 32,199 shares of company stock worth $208,859. Insiders own 5.70% of the company’s stock.

Analyst Ratings Changes

Several research firms have commented on LUNG. Citigroup reaffirmed a “neutral” rating and issued a $7.50 price target (down from $17.00) on shares of Pulmonx in a report on Wednesday, December 11th. Wells Fargo & Company decreased their price objective on Pulmonx from $10.00 to $8.00 and set an “equal weight” rating for the company in a report on Wednesday, December 11th. Finally, Stifel Nicolaus dropped their target price on Pulmonx from $17.00 to $16.00 and set a “buy” rating on the stock in a report on Thursday, October 31st. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $12.75.

About Pulmonx

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.